Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
EMBO Molecular Medicine|May 4, 2016
Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studiesJérémie Decalf, Kristin V Tarbell, Armanda Casrouge, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2022
A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCCEdouard Larrey, Bertille Campion, Manon Evain, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCCFrancisca-Dora Copil, Claudia Campani, Marie Lequoy, et al.Hepatology (Baltimore, Md.)|January 29, 2025
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosisVictor Desplats, Luc Haudebourg, Nicolas Verger, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|August 1, 2020
Transportation and handling of blood samples prior to ammonia measurement in the real life of a large university hospitalFrançoise Imbert-Bismut, Pierre-Emeric Payet, Jamal Alfaisal, et al.JHEP Reports : Innovation in Hepatology|October 29, 2025
Overt hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosisMarika Rudler, Charlotte Bouzbib, Philippe Sultanik, et al.Hepatology (Baltimore, Md.)|October 23, 2023
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Ariane Vallot, Haroun Ghannouchi, et al.JHEP Reports : Innovation in Hepatology|July 22, 2024
Proton pump inhibitor use and risk of hepatic encephalopathy: A multicentre studySimon Johannes Gairing, Chiara Mangini, Lisa Zarantonello, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2015
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapyPhilippe Sultanik, Vincent Mallet, Sylvie Lagaye, et al.Journal of Internal Medicine|November 20, 2023
Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survivalSimon Johannes Gairing, Chiara Mangini, Lisa Zarantonello, et al.Pageof 4